Patent ID: 8828944

Claim:
A method of selecting an optimal therapeutic treatment of cancer in a subject having a tumor, which method comprises: a step of assessing in vitro the sensitivity of a cancer cell from the subject to a first treatment of cancer selected from a chemotherapy using a drug selected from an anthracyclin, a platin, an oxaliplatin, a taxane and an anti-mitotic agent, or radiotherapy, by determining the ability of the tumor cell to induce an anticancer immune response, the inability of the tumor cell to induce an anticancer immune response being indicative of a resistance of the subject to said first treatment of cancer and, if the subject is resistant to said first treatment of cancer, a step of selecting (i) a product allowing or enhancing the secretion of ATP, LysRS and/or IL-8, and/or the exposure of LysRS at the surface of a tumour cell, (ii) a product stimulating the autophagy machinery and/or an ER stress response, (iii) a product triggering the P2RX7 (P2X purinoceptor 7) and/or the NALP3 inflammasome, (iv) a product selected from an antihypertensive or cardiotropic drug or an apyrase inhibitor, or (v) any combination thereof, to be used in combination with the first treatment of cancer as the optimal therapeutic treatment of cancer for the subject.